136834-20-3 Usage
General Description
N6-Benzoyl-2'-Fluoro-2'-deoxyadenosine is a chemical compound that belongs to the nucleoside analog family. It is derived from adenosine, one of the building blocks of DNA and RNA. N6-Benzoyl-2'-Fluoro-2'-deoxyadenosine has a benzoyl group attached to the N6 position and a fluoro group attached to the 2' position of the sugar moiety of adenosine. These modifications in the structure of adenosine alter its properties and can potentially impact its biological activity. N6-Benzoyl-2'-Fluoro-2'-deoxyadenosine may find applications in various fields, including medicinal chemistry research and drug discovery, where it can be used as a tool compound to investigate the effects of specific modifications on nucleoside structures.
Check Digit Verification of cas no
The CAS Registry Mumber 136834-20-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,6,8,3 and 4 respectively; the second part has 2 digits, 2 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 136834-20:
(8*1)+(7*3)+(6*6)+(5*8)+(4*3)+(3*4)+(2*2)+(1*0)=133
133 % 10 = 3
So 136834-20-3 is a valid CAS Registry Number.
136834-20-3Relevant articles and documents
CYCLIC DINUCLEOTIDE COMPOUND AND USES THEREOF
-
Paragraph 0076-0079, (2021/11/05)
Provided are a compound of formula (I), an optical isomer thereof, a pharmaceutically acceptable salt thereof, uses of said compound acting as a STING agonist.
CYCLIC DINUCLEOTIDES AS STING AGONISTS
-
Page/Page column 109; 138; 156; 157; 158; 174; 175, (2018/08/20)
Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R, R1B, R1C, R2B
INHIBITORS OF S-ADENOSYL-L-METHIONINE DECARBOXYLASE
-
, (2009/01/23)
Novel mechanism-based inhibitors of S-adenosyl-L-methionine decarboxylase are provided. These compounds of formula (1) inhibit the life cycle of trypanosomes, and are useful to treat subjects infected with African trypanosomes. The invention includes pharmaceutical compositions and methods of using the compounds of formula (1).